12 results about "Cathepsin L" patented technology

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The present invention relates to a cathepsin K inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (I), wherein (X1) is the amino acid K; (X2) is an amino acid selected from R and W, and is preferably R; (X3) is an amino acid selected from R and W, and is preferably R; (X4) is the amino acid L; (X5) is an amino acid selected from Y, V and W, and is preferably V or Y, and is most preferably V; (X6) is an amino acid selected from I, M, L, W and R, and is preferably I, L or W; and is most preferably I; (X7) is an amino acid selected from H, W, A T, R; and is preferably H or R, and is most preferably R; and (Y) is a Michael acceptor. The present invention also relates to a cathepsin L inhibitor comprising or consisting of Formula (II) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (II), wherein (X1) is the amino acid K; (X2) is the amino acid R; (X3) is an amino acid selected from R, L and M, and is preferably L; (X4) is an amino acid selected from L, W, F and Y, and is preferably W; (X5) is an amino acid selected from V, H and R, and is preferably V; (X6) is an amino acid selected from M, L, I, W and R, and is preferably L; (X7) is an amino acid selected from W, A T, R; and is preferably W; and (Y) is a Michael acceptor.

A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and / or human cathepsin L inhibitor, and / or may be used in the preparation of a medicament for treating and / or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and / or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

The present disclosure provides a plurality of compounds. The compounds can inhibit cathepsin L (CatL). Compositions comprising at least one of these compounds are also provided. Methods for treating or preventing one or more CatL-associated diseases in a subject are also provided. The method may include administering the composition to the subject.

The present invention relates to an anti-cancer agent screening method comprising the steps of evaluating the binding capacity of a candidate compound to the Cys25 and / or Met70 site of cathepsin L (CTSL), and determining the anti-cancer activity of the selected candidate compound based on the binding capacity. The invention firstly determines that 25th cysteine (Cys25) / 70th methionine (Met70) on CTSL protein is a key binding site for screening a high-affinity inhibitor of the CTSL protein, and proves that SQB1C can specifically target the 25th cysteine (Cys25) / 70th methionine (Met70) on CTSL through molecular docking, affinity experiments and key binding site mutation experiments. Functional experiments show that SQB1C can efficiently inhibit the activity of CTSL, can significantly inhibit the growth and metastasis of prostatic cancer by remodeling a tumor immune microenvironment, shows good biological safety, and provides candidate compounds and theoretical basis for developing a novel targeted therapy strategy.

The invention relates to the technical field of biological pharmacy, in particular to application of amantadine in preparation of a medicine for treating myocardial injury. It is found for the first time that amantadine can significantly inhibit the activity of cathepsin L and block lysosome-dependent cell death in an inflammatory environment, so that myocardial cell damage is relieved. In-vivo experiments construct an inflammatory myocardial injury mouse model through intramyocardial injection of coxsackie virus B3, and results show that intraperitoneal injection of amantadine effectively inhibits the activity of CTSL in myocardial tissue, remarkably improves the cardiac function of a model mouse, reduces the death rate, and has a good application prospect under the conditions that the virus infection efficiency is not affected and inflammatory cell infiltration of the myocardial tissue is not remarkably reduced. Meanwhile, myocardial fibrosis and pathological cardiac remodeling are relieved. According to the application, amantadine is reported to directly inhibit myocardial cell death in an inflammatory environment instead of playing an indirect myocardial cell protection role through antiviral and anti-inflammatory effects, and a new drug strategy is provided for treatment of inflammatory myocardial injury.

Disclosed herein are compounds. The compounds are capable of inhibiting Cathepsin L (CatL). Also disclosed herein are compositions comprising at least one of the compounds. Also provided herein are methods of treating or preventing one or more CatL-related diseases. The methods can comprise administering the compositions to a subject.

The invention relates to the technical field of biology, in particular to application of cathepsin L and a product for predicting ovulation. According to the present invention, the first research results show that whether ovulation can be accurately determined according to the CTSL concentration in the female mammal body fluid such as urine and / or blood, the ovulation time can be accurately predicted, the accuracy is significantly higher than the luteinizing hormone (LH) determination method, and the method can be widely used for mammal breeding and human ovulation monitoring, fertility control or contraception.

In the present invention, it has been confirmed that cathepsin L (CTSL) is a dual-action target capable of simultaneously inhibiting tumor progression and CD8⁺ T cell-mediated muscle wasting. That is, pharmacological inhibition of CTSL not only alleviated muscle wasting induced by anti-PD-L1, but also further inhibited tumor growth through down-regulation of BNIP3. As a result, the present invention demonstrates that CTSL acts as a dual-action target that enhances anticancer efficacy while alleviating muscle-specific irAEs, which suggests a new strategic approach that can overcome the clinical limitations of ICIs and improve therapeutic efficacy.

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

Provided herein is a plurality of the compounds. The compounds are capable of inhibiting Cathepsin L (CatL). A composition including at least one of these compounds is also provided. A method for treating or preventing one or more CatL-related diseases in a subject is further provided. The method may include administering the composition to the subject.